SYNlogic, Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a significant decline in both revenue and operating expenses compared to the same periods in 2024. The company did not generate any revenue during the three and nine months ended September 30, 2025, a decrease from $8,000 in revenue reported for the same period in 2024. The net loss for the third quarter was $2.3 million, compared to a loss of $117,000 in the prior year. For the nine-month period, the net loss was $2.5 million, a substantial improvement from a loss of $22.6 million in 2024.
Operating expenses for SYNlogic also saw a notable reduction, totaling $991,000 for the third quarter of 2025, down from $748,000 in the same quarter of 2024. For the nine months ended September 30, 2025, total operating expenses were $2.7 million, significantly lower than the $39.2 million reported in the previous year. The decrease in expenses was primarily attributed to the discontinuation of the Synpheny-3 clinical trial and a corporate restructuring that resulted in a workforce reduction, leaving only one full-time employee.
In terms of strategic developments, SYNlogic has shifted its focus following the discontinuation of its pivotal study for labafenogene marselecobac (SYNB1934) as a treatment for phenylketonuria (PKU). The company is currently exploring strategic alternatives, including potential mergers or sales, as well as collaborations and licensing opportunities. This strategic pivot is part of a broader effort to enhance shareholder value amid ongoing operational challenges.
The company’s financial position as of September 30, 2025, showed total assets of $16.6 million, down from $19.8 million at the end of 2024. Cash and cash equivalents decreased to $15.6 million from $18.9 million. Total liabilities also decreased to $6.2 million from $7.1 million, primarily due to reductions in accrued expenses and accounts payable. The accumulated deficit stood at $444.2 million, reflecting the ongoing challenges in achieving profitability.
Looking ahead, SYNlogic anticipates that its current cash reserves will be sufficient to fund operations for at least the next 12 months. The company plans to maintain its focus on evaluating strategic alternatives while managing its expenses. However, it acknowledges the uncertainty surrounding future revenue generation, as it has not yet achieved regulatory approval for any of its product candidates. The company remains committed to exploring options that could lead to potential partnerships or other strategic transactions to enhance its market position.
About SYNLOGIC, INC.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.